Studies about ibs-smart®

  • The validation study for ibs-smart® shows that elevated biomarkers indicate IBS with up to 100% positive predictive value. Furthermore, this test is highly specific in distinguishing between IBS and IBD. View study
  • A review conducted at the Mayo Clinic of forty studies concluded that 1 in 9 (11%) patients who experience food poisoning develop IBS. View study
  • An assessment of these biomarkers in IBS subtypes showed that they have broad applicability in diagnosing patients with IBS-D or IBS-M (IBS with a diarrheal component). View study
  • The American College of Gastroenterology’s Clinical Guidelines for the Management of IBS suggest “a positive diagnostic strategy as compared to a diagnostic strategy of exclusion…to improve time to initiate appropriate therapy….and to improve cost-effectiveness. View study
  • A review in Digestive Diseases and Sciences on the Microbiome and IBS provided an overview on the pathophysiology of post-infectious IBS along with a discussion on treatment options. View study